MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN) today announced five presentations of its anti-cancer drug, GRN163L, given at this year’s American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA. As in previous annual AACR meetings, telomerase was a featured topic, with over 50 presentations disclosing new findings, reinforcing the importance of telomerase as a universal cancer target for drug and vaccine development.
